What Happens During an Aortic Dissection?

http://www.iradonline.org/about.html

Information for Patients from the International Registry of Acute Aortic Dissection

An aortic dissection is a tear in the wall of the aorta that allows blood to flow within the layers of the aorta. Early diagnosis and treatment of this illness is critical for survival. Certain types (Type A) of dissections, if left untreated, kill 33% of patients within the first 24 hours, 50% of patients within 48 hours, and 75% of patients within 2 weeks.

Advertisements

EHJ: Magnetic resonance imaging safety in pacemaker and implantable cardioverter defibrillator patients: how far have we come?

http://eurheartj.oxfordjournals.org/content/36/24/1505.abstract?etoc

Magnetic resonance imaging safety in pacemaker and implantable cardioverter defibrillator patients: how far have we come? | European Heart Journal// <!–
window.jQuery || document.write("\x3C/script>”)
//–>// // <!–
window.jQuery.ui || document.write("\x3C/script>”)
//–>// <!–
window.jQuery.ui || document.write("\x3C/script>”)
//–>// //

Peter Nordbeck , Georg Ertl , Oliver Ritter
// <!–
window.jQuery || document.write("\x3C/script>”)
//–>// // <!–
window.jQuery.ui || document.write("\x3C/script>”)
//–>// <!–
window.jQuery.ui || document.write("\x3C/script>”)
//–>// //

Abstract

Magnetic resonance imaging (MRI) has long been regarded a general contraindication in patients with cardiovascular implanted electronic devices such as cardiac pacemakers or cardioverter defibrillators (ICDs) due to the risk of severe complications and even deaths caused by interactions of the magnetic resonance (MR) surrounding and the electric devices. Over the last decade, a better understanding of the underlying mechanisms responsible for such potentially life-threatening complications as well as technical advances have allowed an increasing number of pacemaker and ICD patients to safely undergo MRI. This review lists the key findings from basic research and clinical trials over the last 20 years, and discusses the impact on current day clinical practice. With ‘MR-conditional’ devices being the new standard of care, MRI in pacemaker and ICD patients has been adopted to clinical routine today. However, specific precautions and specifications of these devices should be carefully followed if possible, to avoid patient risks which might appear with new MR technology and further increasing indications and patient numbers.

CHINA 8 – CONTEMPORARY ART FROM CHINA AT RHINE & RUHR

http://china8.de/en/

Eight cities along the Rhine and Ruhr, nine museums, around 120 artists – the CHINA 8 exhibition is the most comprehensive survey of contemporary Chinese art held in Germany to date. Alongside established artists, the positions of younger and newly emerging artists are also represented. Nine museums in Düsseldorf, Duisburg, Essen, Gelsenkirchen, Hagen, Marl, Mülheim an der Ruhr and Recklinghausen have come together for this joint project and will be showing works from the fields of painting, photography, calligraphy, ink drawing, sculpture, installation art and video from 15th May to 13th September 2015. The ‘eight’ in the show’s title is not only the number of the participating cities, but also a significant Chinese lucky number.

NEJM: Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

N Engl J Med. 2015 Apr 16;372(16):1500-9. doi: 10.1056/NEJMoa1500858. Epub 2015 Mar 15.

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Abstract

BACKGROUND:

Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in short-term studies. We conducted two extension studies to obtain longer-term data.

METHODS:

In two open-label, randomized trials, we enrolled 4465 patients who had completed 1 of 12 phase 2 or 3 studies (“parent trials”) ofevolocumab. Regardless of study-group assignments in the parent trials, eligible patients were randomly assigned in a 2:1 ratio to receive eitherevolocumab (140 mg every 2 weeks or 420 mg monthly) plus standard therapy or standard therapy alone. Patients were followed for a median of 11.1 months with assessment of lipid levels, safety, and (as a prespecified exploratory analysis) adjudicated cardiovascular events including death, myocardial infarction, unstable angina, coronary revascularization, stroke, transient ischemic attack, and heart failure. Data from the two trials were combined.

RESULTS:

As compared with standard therapy alone, evolocumab reduced the level of LDL cholesterol by 61%, from a median of 120 mg per deciliter to 48 mg per deciliter (P<0.001). Most adverse events occurred with similar frequency in the two groups, although neurocognitive events were reported more frequently in the evolocumab group. The risk of adverse events, including neurocognitive events, did not vary significantly according to the achieved level of LDL cholesterol. The rate of cardiovascular events at 1 year was reduced from 2.18% in the standard-therapy group to 0.95% in theevolocumab group (hazard ratio in the evolocumab group, 0.47; 95% confidence interval, 0.28 to 0.78; P=0.003).

CONCLUSIONS:

During approximately 1 year of therapy, the use of evolocumab plus standard therapy, as compared with standard therapy alone, significantly reduced LDL cholesterol levels and reduced the incidence of cardiovascular events in a prespecified but exploratory analysis. (Funded by Amgen; OSLER-1 and OSLER-2 ClinicalTrials.gov numbers, NCT01439880 and NCT01854918.).